← Oncology Approval Tracker

FDA DECISION ·

Tevimbra

tislelizumab-jsgr · BeOne Medicines USA

FDA approvalNew dosing regimenEsophageal squamous cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds 400 mg IV every six weeks with platinum-containing chemotherapy for first-line unresectable or metastatic ESCC with tumor PD-L1 expression of at least 1.

LAMPGEN ANALYSIS

Why it matters

This action adds a longer interval to the existing first-line chemotherapy combination indication.

What research teams should watch

Specify which assessments remain linked to chemotherapy and which align with checkpoint dosing.

PRIMARY RECORDS

Sources